Association of codon 72 polymorphism of p53 with lower prostate cancer risk

Henner, W. David; Evans, Adam; Hough, Kristi M.; Harris, Emily; Lowe, Bruce A.; Beer, Tomasz M.

doi:10.1002/pros.10021

Cited by 70 publications

(69 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several groups have reported an association between the R72 p53 variant (binds and inactivates p73 better) and increased risk for epithelial cancer, including gastric cancer and cancer of the breast (Langerod et al, 2002;Bonafe et al, 2003;Buyru et al, 2003;Ohayon et al, 2005), ovary (Pegoraro et al, 2002), esophagus (Kawaguchi et al, 2000), skin (Dokianakis et al, 2000;Bastiaens et al, 2001;Shen et al, 2003;De Oliveira et al, 2004), lung , bladder (Soulitzis et al, 2002), prostate (Henner et al, 2001), and larynx (Sourvinos et al, 2001). In other studies, however, authors have found the opposite correlation, instead demonstrating an association between the P72 (lesser apoptotic) variant and increased risk for other cancer types, including cancer of the thyroid (Granja et al, 2004), nasopharynx (Tsai et al, 2002a, b;Tiwawech et al, 2003), prostate (Suzuki et al, 2003), skin (Chen et al, 2003), urogenital region (Kuroda et al, 2003), and lung Fan et al, 2000;Zhang et al, 2003).…”

Section: The Codon 72 Polymorphismmentioning

confidence: 99%

Polymorphisms in the p53 pathway

2006

View full text Add to dashboard Cite

Section: The Codon 72 Polymorphismmentioning

confidence: 99%

Polymorphisms in the p53 pathway

2006

View full text Add to dashboard Cite

“…19 Although Henner et al found a decreased risk for this same polymorphism in Caucasians. 20 One possible explanation for this discrepancy is the effect of racial differences. We demonstrated that the frequency of the Arg/Pro+Pro/Pro genotype of p53 Arg72Pro tended to increase in PC patients compared to controls (OR = 1.35, 95%CI = 0.78-2.34) suggesting that the p53 codon72 polymorphism alone might not influence prostate cancer risk.…”

Section: Discussionmentioning

confidence: 99%

Mismatch Repair Gene MSH3 Polymorphism is Associated With the Risk of Sporadic Prostate Cancer

et al. 2008

View full text Add to dashboard Cite

Purpose-The mismatch repair (MMR) system is a DNA repair mechanism that corrects mispaired bases during DNA replication errors. Cancer cells deficient in the MMR proteins have a 10 2 -10 3 -fold increase in the mutation rate. Single nucleotide polymorphisms (SNPs) of MMR genes have been shown to cause a reduction in DNA repair activity. We hypothesized that mismatch repair gene polymorphism could be a risk factor for prostate cancer (PC) and that p53 Pro/Pro genotype carriers could influence MSH3 and MSH6 polymorphisms.Material and Methods-DNA samples from 110 cases of prostate cancer and healthy controls (n=110) were analyzed by SSCP and PCR-RFLP to determine the genotypic frequency of five different polymorphic loci on two MMR genes (MSH3 and MSH6) and p53 codon72. The chisquare test was applied to compare the genotype frequency between patients and controls.Results-A significant increase in the G/A+A/A genotype of MSH3 Pro222Pro was observed in patients compared to controls (OR, 1.87; 95% CI, 1.0-3.5). The frequency of A/G + G/G genotypes of MSH3 exon23 Thr1036Ala also tended to increase in patients (OR, 1.57; 95% CI, 0.92-2.72). Among p53 codon72 Arg/Pro + Pro/Pro carriers, the frequency of the AG + GG genotype of MSH3 exon23 was significantly increased in patients compared to controls (OR = 2.1, 95% CI; 1.05-4.34).Conclusion-This is the first report on the association of MSH3 gene polymorphisms in prostate cancer. These results suggest that the MSH3 polymorphism may be a risk factor for prostate cancer.

show abstract

“…According to the inclusion criteria, seven studies (Henner et al, 2001;Suzuki et al, 2003;Huang et al, 2004;Wu et al, 2004;Leiros et al, 2005;Quinones et al, 2006;Ricks-Santi et al, 2010) were included in this meta-analysis and 68 studies were excluded. The flow chart of the study selection is summarized in Figure 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

“…All the articles were written in English. The Hardy-Weinberg equilibrium test was performed on the genotype distribution of the controls in all included studies; all of them except Henner et al (2001) (P < 0.001) and Suzuki et al (2003) (P = 0.03) were in Hardy-Weinberg equilibrium. The characteristics and methodological quality of all studies are summarized in Table 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

“…The polymorphism consists of a single base pair change of either arginine (Arg, CGC) or proline (Pro, CCC), which creates three distinct genotypes, including homozygous for arginine (Arg/ Arg), homozygous for proline (Pro/Pro) and heterozygote (Pro/Arg; Shepherd et al, 2000). Recently, p53 codon 72 polymorphisms have been reported to be associated with prostate cancer (Henner et al, 2001). The aim of our meta-analysis was to investigate the association between p53 codon 72 polymorphism and prostate cancer risk by examining all eligible casecontrol studies published to date.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk

Li¹,

Liu²,

Wu³

et al. 2011

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We examined whether p53 codon 72 polymorphism confers prostate cancer risk by conducting a meta-analysis. Two investigators independently searched the Pubmed, Embase and CBM databases. This meta-analysis was made of seven case-control studies, that included 892 prostate cancer cases and 1020 healthy controls. Meta-analysis results based on all the studies showed no significant association between p53 codon 72 polymorphism and prostate cancer risk in the comparisons of Pro allele vs Arg allele; Pro/Pro + Pro/Arg vs Arg/Arg; Pro/Pro vs Pro/Arg + Arg/Arg; Pro/Pro vs Arg/Arg, and Pro/ Arg vs Arg/Arg [odds ratio (OR) = 1.09, 95% confidence interval (CI) = 0.87-1.36, P = 0.47; OR = 1.22, 95%CI = 0.86-1.73, P = 0.27; OR = 1.03, 95%CI = 0.62-1.72, P = 0.91; OR = 1.22, 95%CI = 0.66-2.26, P = 0.52; OR = 1.25, 95%CI = 0.84-1.87, P = 0.27, respectively]. In 2925 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 10 (4): 2924-2933 (2011) p53 codon 72 polymorphism and prostate cancer risk the subgroup analysis by ethnicity, no association was found between p53 codon 72 polymorphism and prostate cancer risk both in Caucasian and Asian populations. We found no association between p53 codon 72 polymorphism and prostate cancer risk.

show abstract

Association of codon 72 polymorphism of p53 with lower prostate cancer risk

Abstract: Men with the p53 codon 72 Pro/Pro genotype appear to be at reduced risk of prostate cancer.

Cited by 70 publications

References 22 publications

Polymorphisms in the p53 pathway

Polymorphisms in the p53 pathway

Mismatch Repair Gene MSH3 Polymorphism is Associated With the Risk of Sporadic Prostate Cancer

Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk

Contact Info

Product

Resources

About